Reducing stigma and eliminating discrimination associated with HIV status is a key strategy in Pennsylvania’s IHPCP and the HIV Planning Group (HPG) recently identified stigma as the number one threat to HIV prevention and care in the Commonwealth. To better understand HIV-related stigma, the HPG set up a survey for PLWH enrolled in Pennsylvania’s AIDS Drug Assistance Program (ADAP) called the Special Pharmaceutical Benefits Program (SPBP). The SPBP stigma survey aims to assess the prevalence of internalized, anticipated and enacted stigma in healthcare settings, characterize intersectional stigma burden, and evaluate the impact of stigma on health outcomes (medical adherence, viral load, depression, healthcare engagement). In 2020, we received 1,410 survey responses from a diverse sample of PLWH from all seven Ryan White Coalition regions of the Commonwealth. Results will be discussed and shared with the HPG at the February and May 2021 HPG meetings. The SPBP survey findings will support a better understanding of how stigma impacts healthcare experiences and health outcomes of people living with and at risk for HIV and will inform the development of interventions and social marketing campaigns to reduce HIV-related stigma and improve HIV prevention and care outcomes in Pennsylvania. Further, the SPBP survey findings will provide documentation around novel or ongoing and exacerbated issues related to the HIV Care Continuum in PA, which may include such topics as barriers to testing, medication supply or adherence, and RW service. Accordingly, these findings will further the work outlined in the Division’s Grant PS18-1802 strategies through monitoring and evaluating HIV prevention and care activities (Strategy 10) and gathering data to continue conducting effective HIV program activities (Strategy 11).